The dual role of CD6 as a therapeutic target in cancer and autoimmune disease

Autoimmune disease involves loss of tolerance to self-antigen, while progression of cancer reflects insufficient recognition and response of the immune system to malignant cells. Patients with immune compromised conditions tend to be more susceptible to cancer development. On the other hand, cancer...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in medicine 2022-10, Vol.9, p.1026521-1026521
Main Authors: Gurrea-Rubio, Mikel, Fox, David A
Format: Article
Language:English
Subjects:
ALCAM (CD166)
autoimmunity
CD318
CD6
CD8 lymphocytes
Medicine
NK cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c395t-808d74ad3a27a86e75d3e995602f1db3f8ec0267a21ab2cb4d8a3f1f5f8a69953
cites cdi_FETCH-LOGICAL-c395t-808d74ad3a27a86e75d3e995602f1db3f8ec0267a21ab2cb4d8a3f1f5f8a69953
container_end_page 1026521
container_issue
container_start_page 1026521
container_title Frontiers in medicine
container_volume 9
creator Gurrea-Rubio, Mikel
Fox, David A
description Autoimmune disease involves loss of tolerance to self-antigen, while progression of cancer reflects insufficient recognition and response of the immune system to malignant cells. Patients with immune compromised conditions tend to be more susceptible to cancer development. On the other hand, cancer treatments, especially checkpoint inhibitor therapies, can induce severe autoimmune syndromes. There is recent evidence that autoimmunity and cancer share molecular targets and pathways that may be dysregulated in both types of diseases. Therefore, there has been an increased focus on understanding these biological pathways that link cancer and its treatment with the appearance of autoimmunity. In this review, we hope to consolidate our understanding of current and emerging molecular targets used to treat both cancer and autoimmunity, with a special focus on Cluster of Differentiation (CD) 6.
doi_str_mv 10.3389/fmed.2022.1026521
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_aacf40be7be64936b651bbada774986b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aacf40be7be64936b651bbada774986b</doaj_id><sourcerecordid>2728145650</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-808d74ad3a27a86e75d3e995602f1db3f8ec0267a21ab2cb4d8a3f1f5f8a69953</originalsourceid><addsrcrecordid>eNpVkUtr3DAURk1oaUKaH9BN0LKbmephPbwplOkrkNJNAtmJK-lqxsG2ppJd6L-vpjMNyUpC-u65VzpN847RtRCm-xBHDGtOOV8zypXk7Ky54LxTKyPNw6tn-_PmqpRHSikTXLZMvGnOheJaGqYumh93OyRhgYHkNCBJkWw-KwKFAJl3mGGPy9x7MkPe4kz6iXiYPGYCUyCwzKkfx2WqhL4gFHzbvI4wFLw6rZfN_dcvd5vvq9uf3242n25XXnRyXhlqgm4hCOAajEItg8Cuk4ryyIIT0aCvb9LAGTjuXRsMiMiijAZUzYnL5ubIDQke7T73I-Q_NkFv_x2kvLWQ69wDWgAfW-pQO1RtJ5RTkjkHAbRuO6NcZX08svaLq1_qcZozDC-gL2-mfme36bftpO6UURXw_gTI6deCZbZjXzwOA0yYlmK55oa1Uklao-wY9TmVkjE-tWHUHqzag1V7sGpPVmvN9fP5nir-OxR_AW90nrw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728145650</pqid></control><display><type>article</type><title>The dual role of CD6 as a therapeutic target in cancer and autoimmune disease</title><source>PubMed Central</source><creator>Gurrea-Rubio, Mikel ; Fox, David A</creator><creatorcontrib>Gurrea-Rubio, Mikel ; Fox, David A</creatorcontrib><description>Autoimmune disease involves loss of tolerance to self-antigen, while progression of cancer reflects insufficient recognition and response of the immune system to malignant cells. Patients with immune compromised conditions tend to be more susceptible to cancer development. On the other hand, cancer treatments, especially checkpoint inhibitor therapies, can induce severe autoimmune syndromes. There is recent evidence that autoimmunity and cancer share molecular targets and pathways that may be dysregulated in both types of diseases. Therefore, there has been an increased focus on understanding these biological pathways that link cancer and its treatment with the appearance of autoimmunity. In this review, we hope to consolidate our understanding of current and emerging molecular targets used to treat both cancer and autoimmunity, with a special focus on Cluster of Differentiation (CD) 6.</description><identifier>ISSN: 2296-858X</identifier><identifier>EISSN: 2296-858X</identifier><identifier>DOI: 10.3389/fmed.2022.1026521</identifier><identifier>PMID: 36275816</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>ALCAM (CD166) ; autoimmunity ; CD318 ; CD6 ; CD8 lymphocytes ; Medicine ; NK cells</subject><ispartof>Frontiers in medicine, 2022-10, Vol.9, p.1026521-1026521</ispartof><rights>Copyright © 2022 Gurrea-Rubio and Fox.</rights><rights>Copyright © 2022 Gurrea-Rubio and Fox. 2022 Gurrea-Rubio and Fox</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-808d74ad3a27a86e75d3e995602f1db3f8ec0267a21ab2cb4d8a3f1f5f8a69953</citedby><cites>FETCH-LOGICAL-c395t-808d74ad3a27a86e75d3e995602f1db3f8ec0267a21ab2cb4d8a3f1f5f8a69953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579686/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579686/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36275816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gurrea-Rubio, Mikel</creatorcontrib><creatorcontrib>Fox, David A</creatorcontrib><title>The dual role of CD6 as a therapeutic target in cancer and autoimmune disease</title><title>Frontiers in medicine</title><addtitle>Front Med (Lausanne)</addtitle><description>Autoimmune disease involves loss of tolerance to self-antigen, while progression of cancer reflects insufficient recognition and response of the immune system to malignant cells. Patients with immune compromised conditions tend to be more susceptible to cancer development. On the other hand, cancer treatments, especially checkpoint inhibitor therapies, can induce severe autoimmune syndromes. There is recent evidence that autoimmunity and cancer share molecular targets and pathways that may be dysregulated in both types of diseases. Therefore, there has been an increased focus on understanding these biological pathways that link cancer and its treatment with the appearance of autoimmunity. In this review, we hope to consolidate our understanding of current and emerging molecular targets used to treat both cancer and autoimmunity, with a special focus on Cluster of Differentiation (CD) 6.</description><subject>ALCAM (CD166)</subject><subject>autoimmunity</subject><subject>CD318</subject><subject>CD6</subject><subject>CD8 lymphocytes</subject><subject>Medicine</subject><subject>NK cells</subject><issn>2296-858X</issn><issn>2296-858X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtr3DAURk1oaUKaH9BN0LKbmephPbwplOkrkNJNAtmJK-lqxsG2ppJd6L-vpjMNyUpC-u65VzpN847RtRCm-xBHDGtOOV8zypXk7Ky54LxTKyPNw6tn-_PmqpRHSikTXLZMvGnOheJaGqYumh93OyRhgYHkNCBJkWw-KwKFAJl3mGGPy9x7MkPe4kz6iXiYPGYCUyCwzKkfx2WqhL4gFHzbvI4wFLw6rZfN_dcvd5vvq9uf3242n25XXnRyXhlqgm4hCOAajEItg8Cuk4ryyIIT0aCvb9LAGTjuXRsMiMiijAZUzYnL5ubIDQke7T73I-Q_NkFv_x2kvLWQ69wDWgAfW-pQO1RtJ5RTkjkHAbRuO6NcZX08svaLq1_qcZozDC-gL2-mfme36bftpO6UURXw_gTI6deCZbZjXzwOA0yYlmK55oa1Uklao-wY9TmVkjE-tWHUHqzag1V7sGpPVmvN9fP5nir-OxR_AW90nrw</recordid><startdate>20221005</startdate><enddate>20221005</enddate><creator>Gurrea-Rubio, Mikel</creator><creator>Fox, David A</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221005</creationdate><title>The dual role of CD6 as a therapeutic target in cancer and autoimmune disease</title><author>Gurrea-Rubio, Mikel ; Fox, David A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-808d74ad3a27a86e75d3e995602f1db3f8ec0267a21ab2cb4d8a3f1f5f8a69953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>ALCAM (CD166)</topic><topic>autoimmunity</topic><topic>CD318</topic><topic>CD6</topic><topic>CD8 lymphocytes</topic><topic>Medicine</topic><topic>NK cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gurrea-Rubio, Mikel</creatorcontrib><creatorcontrib>Fox, David A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gurrea-Rubio, Mikel</au><au>Fox, David A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The dual role of CD6 as a therapeutic target in cancer and autoimmune disease</atitle><jtitle>Frontiers in medicine</jtitle><addtitle>Front Med (Lausanne)</addtitle><date>2022-10-05</date><risdate>2022</risdate><volume>9</volume><spage>1026521</spage><epage>1026521</epage><pages>1026521-1026521</pages><issn>2296-858X</issn><eissn>2296-858X</eissn><abstract>Autoimmune disease involves loss of tolerance to self-antigen, while progression of cancer reflects insufficient recognition and response of the immune system to malignant cells. Patients with immune compromised conditions tend to be more susceptible to cancer development. On the other hand, cancer treatments, especially checkpoint inhibitor therapies, can induce severe autoimmune syndromes. There is recent evidence that autoimmunity and cancer share molecular targets and pathways that may be dysregulated in both types of diseases. Therefore, there has been an increased focus on understanding these biological pathways that link cancer and its treatment with the appearance of autoimmunity. In this review, we hope to consolidate our understanding of current and emerging molecular targets used to treat both cancer and autoimmunity, with a special focus on Cluster of Differentiation (CD) 6.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>36275816</pmid><doi>10.3389/fmed.2022.1026521</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2296-858X
ispartof Frontiers in medicine, 2022-10, Vol.9, p.1026521-1026521
issn 2296-858X
2296-858X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_aacf40be7be64936b651bbada774986b
source PubMed Central
subjects ALCAM (CD166)
autoimmunity
CD318
CD6
CD8 lymphocytes
Medicine
NK cells
title The dual role of CD6 as a therapeutic target in cancer and autoimmune disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T03%3A26%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20dual%20role%20of%20CD6%20as%20a%20therapeutic%20target%20in%20cancer%20and%20autoimmune%20disease&rft.jtitle=Frontiers%20in%20medicine&rft.au=Gurrea-Rubio,%20Mikel&rft.date=2022-10-05&rft.volume=9&rft.spage=1026521&rft.epage=1026521&rft.pages=1026521-1026521&rft.issn=2296-858X&rft.eissn=2296-858X&rft_id=info:doi/10.3389/fmed.2022.1026521&rft_dat=%3Cproquest_doaj_%3E2728145650%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c395t-808d74ad3a27a86e75d3e995602f1db3f8ec0267a21ab2cb4d8a3f1f5f8a69953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2728145650&rft_id=info:pmid/36275816&rfr_iscdi=true